Dewpoint Therapeutics and ConcertAI Announce the First Phase of their Translational Oncology Partnership
BOSTON and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186. Numerous tumor types …